Clareo Health | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of ulcerative colitis (UC)
Has moderately to severely active UC as defined by 3-component Modified Mayo score
Must have corticosteroid dependence or have had no response, insufficient response, loss of response, and/or intolerance to at least one of the following therapies: corticosteroid, immunosuppressants, or an approved anti-tumor necrosis factor (anti-TNF), anti-integrin, anti-interleukin 12/23 (anti-IL12/23), Janus kinase (JAK) inhibitor, Sphingosine 1-phosphate receptor (S1PR) modulator.
You may not be if
Has diagnosis of Crohn's disease or indeterminate colitis
Has current evidence of fulminant colitis, toxic megacolon, bowel perforation, total proctocoloectomy or partial colectomy
Has current or impending need for colostomy or ileostomy
Has had surgical bowel resection within 3 months before screening
Has past or current evidence of definite low-grade or high-grade colonic dysplasia not completely removed
